Apomorphine
- Generic Name
- Apomorphine
- Brand Names
- Apokyn
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17NO2
- CAS Number
- 58-00-4
- Unique Ingredient Identifier
- N21FAR7B4S
- Background
Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884. Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.
...
- Indication
Apomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.
- Associated Conditions
- Mobility decreased
- Associated Therapies
- -
FDA to decide on SPN-830 apomorphine pump approval Feb. 1
FDA sets Feb. 1, 2025, as goal date for deciding on Supernus' apomorphine infusion pump, SPN-830, for treating Parkinson’s off episodes. SPN-830, a portable electronic pump, aims to reduce off episodes by continuously delivering apomorphine subcutaneously. Phase 3 trials TOLEDO and INFUS-ON showed sustained benefits in reducing daily off time. Supernus has faced multiple resubmissions and FDA requests for additional data.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath